证券代码：688314 证券简称：康拓医疗 公告编号：2023-023 西安康拓医疗技术股份有限公司 第二届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 西安康拓医疗技术股份有限公司(以下简称"公司")第二届监事会第五次会 议于 2023 年 8 月 14 日在公司会议室以现场的方式召开，会议通知已于 2023 年 8 月 3 日通过邮件的方式送达全体监事。本次会议由监事会主席帖凯先生主持， 会议应出席监事 3 人，实际出席监事 3 人。会议召开符合《中华人民共和国公司 法》《上海证券交易所科创板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《西安康拓医疗技术股份有限公司章程》的规定，会议召开合法、 有效。 二、监事会会议审议情况 经与会监事审议表决，形成会议决议如下: （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 经审核，监事会认为：公司 2023 年半年度报告及其摘要的编制和审 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-024 西安康拓医疗技术股份有限公司 2023年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理， ...

证券代码：688314 证券简称：康拓医疗 公告编号：2023-018 西安康拓医疗技术股份有限公司 为充分尊重投资者、提升交流的针对性，投资者可于 2023 年 5 月 14 日 17:00 前通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。欢迎广大投资者积极参与本次网上说明会。 特此公告。 西安康拓医疗技术股份有限公司董事会 2023 年 5 月 9 日 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日发布公司 2022 年年度报告，为促进公司规范运作、健康发展，增强公司信息 透明度，加强与广大投资者沟通交流，进一步提升投资者关系管理水平，公司将 于 2023 年 5 月 16 日参与"2023 年陕西辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"。 届时，公司董事长胡立人先生，董事会秘书周欢先生，财务总监沈亮先生（如 有特殊情况，参会人员将可能进行调整）将通过互动平台与投资者进行网络沟通 和交流，欢迎广大投资者踊跃参加。 活动时间：2023 年 5 月 16 日 15:00-17:00。 ...

Financial Performance - The company achieved operating revenue of CNY 239.95 million in 2022, an increase of 12.89% compared to 2021[20]. - Net profit attributable to shareholders was CNY 75.70 million, a decrease of 7.26% from the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 67.98 million, an increase of 2.38% year-on-year[20]. - The company's cash flow from operating activities was CNY 91.98 million, down 10.95% from 2021[18]. - The total assets at the end of 2022 were CNY 638.14 million, an increase of 11.29% compared to the end of 2021[18]. - Basic earnings per share decreased to CNY 1.30, down 17.20% from 2021[19]. - The weighted average return on equity decreased to 14.64%, down 6.2 percentage points from 2021[19]. - The company reported a net profit margin of 722.32% for the year[136]. - The company's total revenue for the year reached approximately 22,011.93 million RMB, representing a 53.07% increase compared to the previous year[95]. Dividend and Share Capital - The company plans to distribute a cash dividend of 5.20 RMB per 10 shares, totaling approximately 30.17 million RMB, which represents 39.86% of the net profit attributable to shareholders for 2022[4]. - The company will increase its total share capital from 58,027,980 shares to 81,239,172 shares after a capital reserve conversion of 4 shares for every 10 shares held[4]. - The total cash dividend amount accounted for 39.86% of the net profit attributable to ordinary shareholders in the consolidated financial statements[162]. - The company has implemented a cash dividend policy that is compliant with its articles of association and shareholder resolutions[159]. Research and Development - The company’s R&D investment accounted for 7.63% of operating revenue, a decrease of 0.28 percentage points from the previous year[19]. - The total R&D investment for the year was ¥18,301,085.39, an increase of 8.90% compared to the previous year[66]. - The cumulative number of patents held by the company reached 45, including 13 invention patents and 22 utility model patents[64]. - The company has obtained 6 new invention patents and 8 utility model patents during the reporting period, totaling 14 new patents[64]. - The company is developing a 3D printing technology using SLS for personalized processing of PEEK powder, aimed at producing skull repair plates[68]. - The company is also working on an antibacterial coating for drainage catheters, with an investment of ¥1,500,000[69]. - The company has initiated multiple R&D projects, including maxillofacial repair and antibacterial coating drainage tubes, aimed at expanding its product line in niche markets[75]. Market Expansion and Product Development - The company plans to continue promoting PEEK bone plates in the U.S. and increase investment in dental and thoracic surgery products[20]. - The company has gained market access in nearly 30 countries or regions overseas, with ongoing expansion efforts[39]. - The company is focusing on optimizing its product structure and enhancing its product pipeline to strengthen its market position in the neurosurgery field[33]. - The company aims to enhance its market share in the neurosurgery sector while expanding into overseas markets, particularly in the fields of thoracic and oral surgery[124]. - The company plans to respond to regional bulk procurement policies in neurosurgery to increase sales volume and market share[126]. - The company is exploring potential mergers and acquisitions to strengthen its market position[136]. Governance and Compliance - The company has a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[4]. - The company has no special arrangements for corporate governance[6]. - The company has established a comprehensive internal control system, which includes 103 revised clauses across nine governance-related regulations[164]. - The company has maintained a stable shareholding structure, with no significant changes reported during the period[132]. - The company has a structured approach to remuneration, referencing industry standards and individual responsibilities[143]. - The company has appointed independent directors to ensure compliance and strategic guidance in its operations[142]. Operational Efficiency and Cost Management - The company has transitioned the production of BIOPLATE titanium products to domestic facilities, enhancing operational efficiency and reducing costs[41]. - The company has implemented lean production practices to reduce waste and improve efficiency, contributing to carbon reduction efforts[177]. - The company has a robust quality management system, ensuring compliance with domestic quality standards and obtaining FDA and CE certifications for multiple products, which guarantees high quality and stability[77]. - The company has established a supplier evaluation system to ensure fair contracts and protect supplier rights[182]. Employee and Talent Management - The company has increased its workforce by 25.73%, with a 30.12% rise in sales and R&D personnel, improving its talent structure[40]. - The company plans to establish an online training platform for all employees to enhance soft skills and meet career development needs[157]. - The company aims to deepen training for key positions and improve project management skills to optimize talent development[157]. - The employee composition includes 101 production personnel, 58 sales personnel, 50 technical personnel, 11 financial personnel, and 39 administrative personnel[154]. Environmental Responsibility - The company invested 57,800 RMB in environmental protection during the reporting period[168]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[170]. - The company has implemented a waste management system for solid waste, with a total of 40m² for general waste storage and 10m² for hazardous waste storage[174]. - The company emphasizes environmental protection by ensuring that all waste management practices meet relevant standards[176]. Risks and Challenges - The company faces risks related to new product development and registration failures, which could adversely affect its long-term core competitiveness[80]. - The company is exposed to risks from rapid technological iterations and changing market demands, which could impact the application prospects of its ongoing projects[80]. - The company has a high dependency on its neurosurgical cranial repair fixation products, which accounted for 94.87% of its main business revenue in 2022, posing a risk if market conditions change[83]. - The company is facing challenges in the neurosurgery market due to low industry ceilings and cross-industry competition, prompting a strategy to acquire leading technologies and products through mergers and acquisitions[128].

Financial Performance - The company's operating revenue for Q1 2023 was ¥64,642,702.97, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders for the same period was ¥19,419,917.13, reflecting a growth of 7.70% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.33, showing an increase of 6.45% from the same period last year[6] - The net profit for Q1 2023 was CNY 19,079,127.44, representing an increase of 8.5% compared to CNY 17,578,386.38 in Q1 2022[18] - Total revenue from operating activities reached CNY 78,281,483.00, up from CNY 58,527,987.95 in the same period last year, indicating a growth of 33.7%[21] - The total comprehensive income for the period was CNY 18,884,533.92, compared to CNY 17,491,604.14 in the same quarter last year, showing an increase of 8.0%[19] Research and Development - Research and development expenses totaled ¥4,000,571.62, which is an increase of 61.23% year-on-year, indicating a significant investment in innovation[6] - Research and development expenses increased to CNY 4,000,571.62, compared to CNY 2,481,241.25 in the previous year, reflecting a growth of 61.4%[18] Cash Flow and Assets - The net cash flow from operating activities was ¥13,837,410.61, which represents a decline of 11.62% year-on-year[5] - Cash and cash equivalents decreased to RMB 255,710,751.50 as of March 31, 2023, down from RMB 349,241,669.41 at the end of 2022, a decline of 26.7%[14] - The company reported a net cash flow from operating activities of CNY 13,837,410.61, a decrease from CNY 15,656,175.96 in Q1 2022[22] - The company incurred a net cash outflow from investing activities of CNY -108,821,161.64, an improvement from CNY -170,936,303.22 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥645,679,581.22, an increase of 1.18% from the end of the previous year[6] - The total assets as of March 31, 2023, were RMB 645,679,581.22, compared to RMB 638,135,743.88 at the end of 2022, showing a slight increase of 1.1%[16] - The total liabilities decreased to RMB 85,113,166.39 as of March 31, 2023, from RMB 96,462,236.78 at the end of 2022, a reduction of 11.4%[16] - The equity attributable to shareholders increased to RMB 562,507,080.16 as of March 31, 2023, compared to RMB 543,283,167.02 at the end of 2022, an increase of 3.5%[16] Shareholder Information - The company had a total of 3,366 common shareholders at the end of the reporting period[10] - The largest shareholder, Hu Liren, holds 48.54% of the shares, amounting to 28,168,420 shares[10] Operational Efficiency - The total operating costs for Q1 2023 amounted to RMB 41,550,307.81, up from RMB 31,854,707.27 in Q1 2022, reflecting a growth of 30.5%[17] - The company reported a net profit margin improvement due to increased revenue and controlled costs, although specific profit figures were not disclosed in the provided content[17] - Sales and service cash receipts totaled CNY 75,942,249.47, up from CNY 57,473,707.41 in Q1 2022, marking a growth of 32.3%[20] Strategic Focus - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the provided content[17] - The company continues to focus on enhancing its financial position through strategic asset management and investment in growth opportunities[24]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.20 RMB per 10 shares (including tax) and to increase capital by 4 shares for every 10 shares held, resulting in a total cash dividend of 30,174,549.60 RMB and a capital increase of 23,211,192 shares[4]. - The cash dividend represents 39.86% of the net profit attributable to shareholders for the year 2022[4]. - The company distributed a cash dividend of 0.62 CNY per share, totaling 35,977,347.60 CNY for the reporting period[158]. - The cash dividend amount accounted for 39.86% of the net profit attributable to ordinary shareholders in the consolidated financial statements[162]. - The company revised its profit distribution policy to include specific conditions and decision-making procedures for cash dividends, ensuring protection for minority investors[158]. Financial Performance - The company achieved operating revenue of CNY 239,948,744.59 in 2022, representing a year-on-year increase of 12.89%[18]. - The net profit attributable to shareholders was CNY 75,698,150.91, a decrease of 7.26% compared to the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 67,982,008.71, an increase of 2.38% year-on-year[18]. - The company's cash flow from operating activities was CNY 91,975,607.52, down 10.95% from the previous year[18]. - The basic earnings per share decreased by 17.20% to CNY 1.30 in 2022[19]. - The company's total assets increased by 11.29% to CNY 638,135,743.88 at the end of 2022[18]. - The company achieved a gross margin of 81.94% in the medical device sector, with a revenue increase of 11.29% compared to the previous year[89]. - The company's total revenue for the year reached approximately 22,011.93 million, representing a 53.07% increase compared to the previous year[95]. - The company reported a gross margin of 45%, an improvement from 42% in the previous year[139]. Research and Development - The total R&D investment for the year was ¥18,301,085.39, an increase of 8.90% compared to the previous year[66]. - R&D investment as a percentage of operating revenue decreased to 7.63%, down by 0.28 percentage points from the previous year[66]. - The company has developed a full product line for cranial repair and fixation surgeries, including PEEK plates and titanium mesh, addressing diverse clinical needs[75]. - The company is actively pursuing multiple R&D projects, including maxillofacial repair and antibacterial coating drainage catheters, to expand its product offerings[75]. - The company has obtained 6 new invention patents and 8 utility model patents during the reporting period, totaling 14 new patents[64]. - The cumulative number of patents held by the company has reached 45, including 13 invention patents and 22 utility model patents[64]. - The company is developing a 3D printing technology using SLS for personalized processing of PEEK powder, aimed at producing skull repair plates[68]. - The company has improved its core technology for PEEK material, achieving better strength and flexibility in cranial fixation products[62]. Market Expansion and Product Development - The company plans to continue promoting PEEK bone plates in the U.S. and increase investment in dental and thoracic surgery products[20]. - The company is committed to expanding its oral business, which has formed a clear development plan and is expected to grow gradually[32]. - The company is expanding its international presence, with products sold in the US, EU, Brazil, Russia, Australia, and Southeast Asia, contributing to market expansion[77]. - The company plans to continue expanding its product promotion efforts and sales channels to enhance market penetration[86]. - The company is focusing on new product development and technology research to enhance market competitiveness[136]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[139]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[4]. - There are no special arrangements for corporate governance or other significant matters applicable to the company[6]. - The company has not violated any regulatory decision-making procedures in providing guarantees[6]. - The company has established a comprehensive internal control system, which includes 103 revised clauses across nine governance-related regulations[164]. - The company has maintained a stable shareholding structure, with no significant changes reported among major shareholders during the reporting period[135]. - The company has a diverse management team with extensive experience in the medical technology sector[136]. Risks and Challenges - The company has not reported any significant risks that could materially affect its operations during the reporting period[3]. - The company faces risks related to new product development and registration failures, which could adversely affect long-term core competitiveness if projects fail[80]. - The company is exposed to risks from rapid technological iteration and changing market demands, which could impact the application prospects of ongoing projects[80]. - The company has a high dependency on its main product, with 94.87% of revenue coming from cranial repair fixation products in 2022, making it vulnerable to market changes[83]. Employee and Talent Management - The company has increased its workforce by 53 employees, a 25.73% increase year-on-year, with a 30.12% increase in sales and R&D personnel[40]. - The number of R&D personnel increased to 50, representing 19.31% of the total workforce, compared to 41 personnel and 20% in the previous period[74]. - The company plans to establish an online training platform for all employees to enhance soft skills training and meet career advancement needs[128]. - The company aims to optimize its talent management system, including job matrix and compensation assessment, to create a fair and transparent evaluation system[128]. Environmental Responsibility - The company invested 57,800 CNY in environmental protection during the reporting period[168]. - The company did not face any administrative penalties related to environmental issues during the reporting period[170]. - The company has implemented a lean production approach to reduce carbon emissions and improve efficiency, focusing on waste elimination and optimizing processes[177]. - The company has a dedicated emergency response plan for environmental incidents, enhancing its capability to manage public crises related to environmental pollution[175]. Investor Relations - The company held a total of 4 earnings briefings during the reporting period, including 1 online event and 3 specific audience research sessions[186]. - The company received over 100 investor relations emails and answered 117 investor calls, achieving a 100% response rate to 25 inquiries through the Shanghai Stock Exchange's "e-Interaction" platform[186]. - The company maintains a transparent information disclosure process, ensuring timely and accurate communication of significant information to investors[188]. - The company has committed to various share lock-up agreements for its major shareholders, ensuring compliance with regulations[193].

证券代码：688314 证券简称：康拓医疗 公告编号：2023-010 西安康拓医疗技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 03 月 31 日(星期五) 下午 14:00-15:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 24 日(星期五)至 03 月 30 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 年度经营成果、财务状 ...

证券代码：688314 证券简称：康拓医疗 编号：2022-004 西安康拓医疗技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | □√特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □√现场参观 □其他(请文字说明 ) | | | 2022 年 5 月 11 日 | 14:00-16:00 | | | 陕西金资基金 | ...

Group 1: Company Overview and Product Development - The company, Xi'an Kangtuo Medical Technology Co., Ltd., is focused on the development of 3D printed PEEK cranial systems, which received approval for innovative medical device registration in April 2022 [2] - The PEEK bone plate is currently undergoing FDA certification, having entered the administrative review stage [2][4] Group 2: Market Strategy and Financial Performance - The company acknowledges that stock price fluctuations are influenced by macroeconomic factors and industry policies, emphasizing the importance of solid operational management to enhance shareholder value [3] - The company is actively promoting its dental implant products and participating in national procurement initiatives to expand market reach [3][4] Group 3: International Expansion and Future Plans - The overseas market is identified as a new growth source, with a primary focus on the U.S. market for PEEK bone plates [4] - The company has established a marketing team in the U.S. and is working on the commercialization of its products, including a wireless intracranial pressure monitor that has received FDA certification [4]

Financial Performance - The company's operating revenue for Q3 2022 was ¥63,085,811.80, representing a year-over-year increase of 14.10%[5] - Net profit attributable to shareholders decreased by 5.22% to ¥25,756,165.37 for the quarter, while the net profit excluding non-recurring gains and losses was ¥22,145,987.73, down 2.01%[5] - The basic earnings per share for the quarter were ¥0.44, a decrease of 6.38% compared to the same period last year[6] - The weighted average return on equity was 4.97%, down 0.81 percentage points year-over-year[6] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 66,646,445.75, compared to CNY 61,961,081.14 in Q3 2021, reflecting an increase of approximately 7.3%[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥623,455,920.67, an increase of 8.73% compared to the end of the previous year[6] - Total liabilities increased to ¥91,969,716.34 in the third quarter of 2022 from ¥71,984,609.68 in the same quarter of 2021, representing a rise of approximately 27.7%[21] - The total equity attributable to shareholders increased by 5.83% to ¥532,670,720.64 compared to the end of the previous year[6] - The total equity attributable to shareholders increased to ¥532,670,720.64 from ¥503,322,688.90, representing a growth of about 5.8%[21] Cash Flow - Cash flow from operating activities for the year-to-date was ¥74,932,246.33, reflecting a growth of 9.98%[6] - The net cash flow from operating activities for the first nine months of 2022 was CNY 74,932,246.33, up from CNY 68,132,297.09 in the same period of 2021, indicating a growth of about 12.9%[29] - The cash inflow from operating activities totaled CNY 210,741,748.56 in Q3 2022, compared to CNY 188,256,785.37 in Q3 2021, representing an increase of approximately 11.9%[29] - The company's cash and cash equivalents increased to ¥395,643,085.22 in the third quarter of 2022, up from ¥375,769,177.70 in the previous quarter, showing a growth of about 5.1%[20] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 250,652,931.07, compared to CNY 158,674,455.57 at the end of Q3 2021, showing an increase of about 57.8%[30] Research and Development - Research and development (R&D) expenses for the quarter amounted to ¥5,113,614.39, a significant increase of 106.72% year-over-year, reflecting higher personnel costs and new product registration expenses[11] - R&D expenses accounted for 8.11% of operating revenue, up 3.64 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥11,122,398.10, compared to ¥8,228,680.85 in the same period of 2021, indicating an increase of approximately 35.5%[24] - The company invested significantly in R&D, particularly in promoting thoracic and dental products, which impacted net profit growth[16] Revenue Breakdown - The company achieved operating revenue of 178.48 million RMB for the year-to-date period, representing an 18.16% increase year-over-year[16] - Revenue from PEEK material cranial repair products reached 107.52 million RMB, up 21.68% compared to the same period last year[16] - The revenue from titanium material cranial repair products was 54.66 million RMB, marking a 5.20% increase year-over-year[16] - The revenue from PEEK material sternal fixation systems surged to 5.77 million RMB, a remarkable 80.63% increase year-over-year[16] Investment Activities - The net cash flow from investing activities for the first nine months of 2022 was -CNY 114,685,668.05, an improvement from -CNY 185,909,376.41 in the same period of 2021[30] - The total cash inflow from investment activities in Q3 2022 was CNY 528,263,335.50, significantly higher than CNY 238,801,341.14 in Q3 2021, marking an increase of about 108.3%[29] - The total cash outflow from investment activities in Q3 2022 was CNY 642,949,003.55, compared to CNY 424,710,717.55 in Q3 2021, reflecting an increase of approximately 51.5%[30] - The company received CNY 526,000,000.00 from other investment-related cash activities in Q3 2022, compared to CNY 238,000,000.00 in Q3 2021, indicating a growth of about 105.8%[29] Inventory and Accounts Payable - The company’s inventory stood at approximately 38.62 million RMB as of September 30, 2022[18] - The company reported a decrease in accounts payable from ¥15,026,911.27 in the previous quarter to ¥10,666,174.28 in the current quarter, a reduction of about 29.5%[20] - Deferred income tax assets decreased to ¥2,890,438.58 from ¥3,161,943.61, reflecting a decline of approximately 8.5%[20]